Personalized ‘Brain in a Dish’ Testing: The Future of Antidepressant Selection

Imagine a world where your doctor selects the best antidepressant for you—not based on guesswork or lengthy trial and error, but on hard evidence from your very own cells. In this week’s companion to the podcast episode, Alan Ogden dives deep into the emerging science of personalized brain in a dish testing and how it’s poised to revolutionize antidepressant therapy. Let’s unpack how patient-specific neuron cultures are changing drug matching, reducing trial and error, and creating a new standard for mental health care.

Personalized Drug Matching: Turning Medical Protocols on Their Heads

Alan starts the conversation by highlighting the frustration many patients face with traditional antidepressant selection. As Alan recalls, “I can’t even begin to number the prescriptions that I handed out to people and they come back with a quarter half full bottle or maybe even more. And no, this can’t take this. It’s not working for me. It’s making me feel worse.” For many, finding the right antidepressant can be a long process fraught with side effects, disappointment, and delays in relief.

Enter Dr. Talia Cohen-Salal, CEO and co-founder of NeuroCare, who explains their groundbreaking approach: “The premise is matching the right drug to the right patient instead of a patient trying to get better at the drug that isn’t suited to their biology.” According to Dr. Cohen-Salal, NeuroCare’s process involves taking a simple blood draw, transforming those blood samples into stem cells, and then differentiating those into neurons. “We then have a window into the brain, a model of the brain of that individual patient. We can test all the different antidepressants on that sample, on that brain in a dish instead of in the patient’s brain.”

This method puts the focus squarely on the patient’s actual biology. As Alan notes, “So you do that through pharmacogenetics?” Dr. Cohen-Salal clarifies: “We also include pharmacogenomics. So we also give that report together with the neuronal readout, which allows you to combine not just which drug is best, but also help understand how your lipid metabolism enzymes are going to process those drugs as well.”

Reduction of Trial and Error: Taking the Guesswork Out of Treatment

If you’ve ever switched antidepressants over and over, hoping to land on the right one, you know firsthand how much trial and error is involved. Alan emphasizes how this model addresses that challenge: “We take that period of trial and error out of the patient and into the lab where it belongs.” The patient’s neurons are exposed to multiple antidepressant candidates, and the response is measured directly—no more waiting weeks or months to discover if a medication is working.

As Dr. Cohen-Salal explains, “Then we create a report which has a simple understanding of which drug has the strongest impact on the brain biology.” The result is a personalized recommendation optimized by the patient’s own biology and genetics, offering the potential to accelerate recovery and minimize unnecessary suffering.

Brain in a Dish Models: More Than Just Neurons

One of the fascinating aspects Alan explores is how accurately these models reflect the complexity of the human brain. Dr. Cohen-Salal shares, “What’s important is that the brain in a dish model that we’re using is representative of actually the human brain. We do have both the glial cells, the immune kind of response that might be happening locally, as well as the normal neuronal populations, both positive inhibitory and excitatory neurons.”

This approach ensures that not just neurons, but the broader ecosystem of the brain gets evaluated. As Alan points out in a personal anecdote about brain injury recovery, glial cells play a crucial role in detoxification (through glutathione production). Dr. Cohen-Salal notes that impacts happening on those cell types as a result of antidepressant exposure are detected as well: “That’s how we address those issues.” This gives clinicians a more holistic view of drug effects, potentially revealing hidden side effects or efficacy issues that would be missed in simpler models.

Understanding the Need: Depression, Anxiety, and Beyond

The demand for better mental health treatments is indisputable. Alan shares, “I read this and maybe you can clarify this for me. But one of the articles I read prior to changing from pharmacy to going to genetics was, and I believed it, that close to 60 percent of females in America, that includes Canada, the United States, had been on some sort of either anti-anxiety medication or something for depression, but some something to do with the challenge in their cognitive abilities.” He remarks on the shock of such high numbers and the ongoing misunderstanding surrounding treatment.

Alan explains, “Around 25 percent of the population at some point in their life will have a depressive episode and 8 percent in a given year. But it’s twice as prevalent in women as it is in men… even though it’s more prominent in women, unfortunately, and in men, it’s actually more likely to cause suicide. So suicidality in men as a result of depression is higher.” These observations underscore why personalized medicine is needed: every patient’s experience is different, and so should their treatment protocol.

Expanding Applications: PTSD, Drug Development, and New Frontiers

The conversation also touches on how this approach could benefit other mental health conditions. Alan asks whether PTSD is part of NeuroCare’s protocol. Dr. Cohen-Salal responds, “While our validation studies have been conducted in the depression patient population, because a lot of the drugs that are being used are overlapping antidepressant drugs, antidepressants are being used for PTSD. So we have collaborations here starting it to do clinical trials and PTSD. And some physicians are choosing to use this off label in that area as well.”

This implies that personalized brain in a dish testing could soon support drug matching for PTSD, expanding its utility among veterans, first responders, and others affected by trauma—and potentially informing research in addiction and recovery as well.

• FDA-Approved Scope: NeuroCare’s platform focuses on FDA-approved drugs for depression treatment, ensuring clinical relevance while maintaining regulatory compliance.
• Drug Development Partnerships: The PharmaCare product line allows pharmaceutical partners to test new compounds rapidly using this patient-specific model, including partnerships with those developing psychedelic treatments, ketamine-based therapies, and other emerging compounds.
• Pharmacogenetic Integration: Alan highlights how metabolism—including lipid-processing enzymes—can profoundly affect individual drug response, making the combined genetic and cellular readout a powerful tool.

Challenges and Logistics: Regulatory Hurdles and Accessibility

Of course, cutting-edge science comes with real-world practicalities. Alan asks, “If I’m from Canada, you’re from the U.S., what about a Canadian patient? Is this something that like they would come down there for treatment to have this done?” Dr. Cohen-Salal clarifies that for now, NeuroCare’s platform is regulatory approved in the United States, “so you would have to come to the United States to do that, to do the test for now.” Blood sample transport and regulatory compliance are key factors, and as Alan observes, “It’s important that it’s regulatory approved in the site where the blood was drawn.”

Evolving Science: Hormone Disruptions, New Drug Classes, and the Road Ahead

Alan broadens the discussion by asking about hormone changes, noting trends of “reduction quite a bit earlier in testosterone levels in young men” and “disruptions in women’s hormone panels at an earlier age than before.” While the episode doesn’t dive deeply into hormone-related testing, these kinds of biological trends may become important factors in personalized medicine as the science matures.

The conversation also reflects growing interest in cannabinoids, psychedelics, and other novel drug classes—both from government-supported research and pharmaceutical partners. NeuroCare’s model is poised to support these innovations, integrating them into their platform as they become FDA-approved for depression treatment.

Conclusion: Why Personalized Brain in a Dish Testing Matters

Alan’s exploration of personalized brain in a dish testing reveals a future of mental health care that is guided by each patient’s unique cellular and genetic makeup—not a one-size-fits-all protocol. Patients may soon avoid the frustration and risk of trial-and-error prescribing, getting effective treatments sooner with less side effect burden. As Alan notes, “We are adding some pharmacogenetics to that in the next couple of months, but certainly not to the extent of the protocol that you’re doing.”

For anyone struggling to find the right antidepressant—or for clinicians seeking more effective, science-driven options—this personalized approach represents true progress. If you’re curious about whether personalized brain in a dish testing could help you or someone you love, reach out to providers like NeuroCare or your local physician to explore the latest science and options.

Start the conversation: What would it mean for your mental health journey to select medications based on your own neurons, rather than hope and guesswork? Share your thoughts and questions below, and tune in to Alan’s podcast for ongoing updates as this exciting field evolves.